The global gene therapy market size is expected to reach USD 5.55 billion by 2026, growing at a CAGR of 33.9% over the forecast period, according to a new report by Grand View Research, Inc. Gene therapy is being developed with an aim to identify and cure rare conditions, diseases that have limited treatment options and that need lifelong medication to keep the symptoms in check. For instance, metabolic disorders like lysosomal diseases need constant medical attention with the medication available now, however, gene therapy might become a one-time cure to such diseases.
There are a number of molecules under development due to intense competition. This factor is projected to be the key factor propelling the market growth. In early 2018, there were more than 950 molecules in the pipeline with various regulatory bodies in various clinical phases. However, around 76% of the molecules are in the developmental or preclinical stages and are expected to be available by the late 2020s. Larger pharma/biotech companies are entering into the market by either acquiring the licensing/manufacturing rights from smaller companies that are solely dedicated to gene therapy research or by building a dedicated research portfolio with investments and clinical trials.
These factors are also expected to boost the market growth over the next two decades. Most of the manufacturers are also developing molecules that can help cure various cancers. Growing prevalence of different types of cancer emphasizes the need for the development of robust treatment options. Ongoing developments in cancer gene studies have provided significant information about cancer-related molecular signatures, which in turn, is expected to support the ongoing clinical trials for cancer therapeutics.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
7 gene therapy molecules have been approved by various regulatory bodies. In 2018, the FDA approved 3 molecules
Lentivirus is being used as viral vector of choice for 2 of the 3 molecules approved by the FDA
U.S. and Europe are expected to occupy the largest market shares over the forecast period owing to gene therapy molecules being marketed in these regions
Europe is set to grow at a fast pace due to the growing pipeline molecules and a number of companies competing in the regional market
Key companies in the market are Novartis AG, Gilead Sciences, Inc.; UniQure N.V.; Spark Therapeutics LLC; Bluebird Bio; Juno Therapeutics; GlaxoSmithKline PLC; Celgene Corporation; Shire PLC; Sangamo Biosciences, Inc.; Dimension Therapeutics, Inc.; Voyager Therapeutics, Inc.; Human Stem Cell Institute; Chiesi Farmaceutici S.p.A.; and Bristol-Myers Squibb Company
Grand View Research has segmented the global gene therapy market on the basis of indication, vector, and region:
Gene Therapy Indication Outlook (Revenue, USD Million, 2014 - 2026)
Acute Lymphoblastic Leukemia (ALL)
Inherited Retinal Disease
Large B-Cell Lymphoma
Head & Neck Squamous Cell Carcinoma
Peripheral Arterial Disease
Gene Therapy Vector Outlook (Revenue, USD Million, 2014 - 2026)
Adeno-Associated Virus (AAV)
RetroVirus & Gamma RetroVirus
Modified Herpes Simplex Virus
NON-VIRAL Plasmid Vector
Injection of Naked DNA
Gene Therapy Regional Outlook (Revenue, USD Million, 2014 - 2026)
Rest of the World
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."